191 related articles for article (PubMed ID: 11256023)
21. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
[TBL] [Abstract][Full Text] [Related]
22. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
24. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
[TBL] [Abstract][Full Text] [Related]
25. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
28. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of DACE regimen on relapsed and refractory non-Hodgkin's lymphoma].
Zhang MZ; Zang WP; Song M; Geng L; Li X; Wang RL
Ai Zheng; 2008 Apr; 27(4):435-7. PubMed ID: 18423133
[TBL] [Abstract][Full Text] [Related]
30. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of alternating triple therapy on relapsed or refractory non-Hodgkin's lymphoma].
Tian H; Chen J; Wu Y; Li LL
Ai Zheng; 2008 Jun; 27(6):633-5. PubMed ID: 18570739
[TBL] [Abstract][Full Text] [Related]
33. Low grade malignant non-Hodgkin's lymphomas and peripheral pleomorphic T-cell lymphomas in childhood--a BFM study group report.
Bucsky P; Feller AC; Reiter A; Beck J; Bertram U; Eschenbach C; Gerein V; Lakomek M; Stollmann B; Tausch W
Klin Padiatr; 1990; 202(4):258-61. PubMed ID: 2203939
[TBL] [Abstract][Full Text] [Related]
34. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Dinçol D; Içli F; Karaoğuz H; Cay F; Arican A; Demirkazik A; Akbulut H
Acta Oncol; 1995; 34(7):937-40. PubMed ID: 7492384
[TBL] [Abstract][Full Text] [Related]
35. VB-CHEP chemotherapy regimen for aggressive non-Hodgkin's lymphomas.
Yalçin S; Kars A; Ozişik Y; Tekuzman G; Ozyilkan O; Celik I; Barişta I; Güllü I; Güler N; Baltali E; Firat D
Eur J Haematol; 1998 Oct; 61(4):261-5. PubMed ID: 9820633
[TBL] [Abstract][Full Text] [Related]
36. MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.
Oster W; Forsthuber T; Hennekeuser HH; Gamm H; Lindemann A; Schmitz G; Fuhr HG; Hinterberger R; Kreiter H; Thoenes W
Blut; 1990 Jan; 60(1):23-7. PubMed ID: 1688725
[TBL] [Abstract][Full Text] [Related]
37. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Rummel MJ; Mitrou PS; Hoelzer D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
[TBL] [Abstract][Full Text] [Related]
38. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
[TBL] [Abstract][Full Text] [Related]
39. Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial.
Coutinho F; Manhani AR; Velasquez WS; Del Giglio A
Acta Haematol; 2004; 112(3):121-5. PubMed ID: 15345892
[TBL] [Abstract][Full Text] [Related]
40. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
Rigacci L; Puccini B; Cortelazzo S; Gaidano G; Piccin A; D'Arco A; Freilone R; Storti S; Orciuolo E; Zinzani PL; Zaja F; Bongarzoni V; Balzarotti M; Rota-Scalabrini D; Patti C; Gobbi M; Carpaneto A; Liberati AM; Bosi A; Iannitto E
Ann Hematol; 2012 Jul; 91(7):1013-22. PubMed ID: 22349722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]